By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ProteoThera, Inc.  

Two Newton Executive Park, Suite 203
2227 Washington Street
Newton  Massachusetts  02462  U.S.A.
Phone: n/a Fax: n/a


ProteoThera, Inc. is advancing a proprietary tissue matrix-binding (MB) protein fusion technology, which is being developed to improve clinical efficacy and safety of FDA-approved and validated therapeutics for the treatment of auto-inflammatory diseases and in tissue regeneration. The Company’s internal developments are currently focused on the combined $5B osteoarthritis and acute gout injection therapies markets. The MB targeting technology, which was developed at Brigham and Women’s Hospital and Harvard Medical School, can generate new pharmacokinetic profiles for therapies, transforming systemically delivered drugs into locally delivered proteins, peptides, and small molecules. ProteoThera’s focus on previously validated or approved therapies greatly de-risks the clinical, regulatory, and commercial pathways. By keeping therapies where they are needed to enable therapeutic effect, the MB platform may also improve the safety profile by reducing or eliminating side effects associated with whole-body systemic exposure.

Key Statistics

Ownership: Private

Web Site: ProteoThera


Company News